Skip to main content
. 2016 May 20;7(26):40115–40134. doi: 10.18632/oncotarget.9499

Figure 2. Nutlin-3/RG7388 synergizes with cisplatin in wild-type TP53 ovarian cancer cells.

Figure 2

A. Growth inhibition curves of three wild-type TP53 cell lines exposed to Nutlin-3 and CDDP alone, and in combination at constant 1:1 ratios of 0.25X, 0.5X, 1X, 2X and 4X their respective GI50 concentration for 72 hours. B. Growth inhibition curves of three wild-type TP53 cell lines exposed to RG7388 and CDDP alone, and in combination at constant 1:1 ratios of 0.25X, 0.5X, 1X, 2X and 4X their respective GI50 concentrations for 72 hours. C. The CI values for Nutlin-3/RG7388 in combination with cisplatin at ED50 and the average of CI values at effect levels ED50, ED75 and ED90 in three wild-type TP53 ovarian cancer cell lines. Data are shown as the average of at least 3 independent experiments and error bars represent SEM. Nut-3, Nutlin-3; RG, RG7388; CDDP, cisplatin; CI, Combination Index.